VENCLEXTA® (Venetoclax)

The FDA on April 11, 2016 approved VENCLEXTA® for the treatment of patients with Chronic Lymphocytic Leukemia (CLL) with 17p deletion, as detected by an FDA approved test, who have received at least one prior therapy. VENCLEXTA® tablets are marketed by AbbVie, Inc. and Genentech USA, Inc.